Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase NA 1

Status

Not yet recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 2OTHER_GOV 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1Genitourinary 1

Conditions

Pseudomyxoma Peritonei 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Kidney Transplantation 1

Interventions

Specimen Handling 613pembrolizumab 563Magnetic Resonance Spectroscopy 536Carboplatin 425Cisplatin 375Cyclophosphamide 373Biopsy 357Paclitaxel 306Gemcitabine 303Nivolumab 300Radiotherapy 260Bevacizumab 234Dexamethasone 209fludarabine 205Docetaxel 187durvalumab 182atezolizumab 173Oxaliplatin 172venetoclax 168Fluorouracil 166Rituximab 165Pemetrexed 163Capecitabine 158Doxorubicin 157Radiation 155Radiosurgery 148Etoposide 137Leucovorin 133Ipilimumab 133Lenalidomide 131

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Alemtuzumab × 90 days × Clear all
NCT06084780 2026-06-05

TRANSCAPE

Case Comprehensive Cancer Center

Phase 2 Not yet recruiting
20 enrolled

Pseudomyxoma Peritonei

NCT03821610 2026-05-05

ALL-RIC

University of Birmingham

Phase 2 Active not recruiting
242 enrolled
LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02711202 2026-04-13

Sequential Targeting of Cluster of Differentiation 52 (CD52) and Tumor Necrosis Factor (TNF) Allows Early Minimization Therapy in Kidney Transplantation

Institute for Clinical and Experimental Medicine

Phase NA Completed
20 enrolled 11 charts
Genitourinary

Kidney Transplantation

Data powered by HemOnc (CC BY 4.0) Colophon âš¡